Weiss Asset Management LP Purchases New Shares in IQVIA Holdings Inc. (NYSE:IQV)

Weiss Asset Management LP bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 28,864 shares of the medical research company’s stock, valued at approximately $6,840,000.

Several other hedge funds have also recently bought and sold shares of IQV. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA in the second quarter worth approximately $27,000. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter worth approximately $27,000. Park Place Capital Corp purchased a new position in IQVIA during the third quarter valued at approximately $28,000. Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the 2nd quarter worth $29,000. Finally, International Assets Investment Management LLC bought a new stake in IQVIA in the 2nd quarter worth approximately $32,000. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of NYSE IQV opened at $199.92 on Friday. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a 50 day moving average of $215.82 and a 200 day moving average of $225.33. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $36.29 billion, a price-to-earnings ratio of 26.24, a price-to-earnings-growth ratio of 2.06 and a beta of 1.49.

Analyst Ratings Changes

A number of brokerages recently commented on IQV. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research note on Wednesday. Evercore ISI lowered their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Morgan Stanley reduced their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Finally, Leerink Partners reiterated an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.